KRT19 regulates cell proliferation and migration Abstract Purpose: Keratin19 (KRT19) is the smallest known type I intermediate filament and is used as a marker for RT-PCR-mediated detection of disseminated tumors. In this study, we investigated the functional analysis of KRT19 in human breast cancer.
Results

Silencing of KRT19 expression increases proliferation of breast cancer cells
We established KRT19 silenced cells (KRT19 shRNA cells) and control cells (Cont shRNA cells) using BT474, SKBR3, T47D, MCF7 vec and MCF7 HER2 human breast cancer cell lines and a shRNA transfection system. Western blot and immunocytochemical analyses confirmed the downregulation of KRT19 in KRT19 shRNA cells ( Fig. 1A and quantified in Supplementary Fig. S6A ; Supplementary Fig. S1A and S1B) . We examined the cell morphology and rearrangement of the actin filament cytoskeleton following silencing of KRT19 using F-actin staining and found that KRT19 silencing did not significantly affect cell morphology and actin rearrangement ( Supplementary Fig.   S1B ). First, we compared the cell proliferation rate of KRT19 shRNA cells with that of Cont shRNA cells. As shown in Figure 1B and Supplementary Fig. S1C , the growth rates of five KRT19 shRNA cell lines were up-regulated compared with those of Cont shRNA cell lines, suggesting that KRT19 silencing induced cellular event(s) associated with increased cell proliferation. To confirm the effect of KRT19 on cell proliferation, MTT assays were performed in KRT19 negative/low 293T and MDA-MB-231 cells using KRT19 overexpressing system ( Supplementary Fig. S1E ). The proliferation rates of KRT19 overexpressing cells were down-regulated compared with that of control cells ( Supplementary Fig. S1F ). When the cell cycle profiles of KRT19 shRNA and Cont shRNA cells were compared, we found that the S phase fractions were significantly increased in KRT19 shRNA cells with a concomitant reduction in G1 phase ( Fig. 1C and Supplementary Fig. S1D ). We also investigated the effect of KRT19 silencing on three-dimensional colony formation. The results of both soft agar and matrigel colony formation assays suggest that KRT19 silencing resulted in a significantly increased rate of colony formation ( Fig. 1D and Supplementary Fig. S2A ).
KRT19 silencing up-regulates cell migration, invasion, and survival
Next, we examined the effect of KRT19 silencing on cell migration and invasion. As shown in Figure 2A , 2B, Supplementary Fig. S2B and S2C, the migration and invasion rates of KRT19 shRNA cells were up-regulated compared with those of Cont shRNA cells. To determine the effects of KRT19 silencing on cell survival and apoptosis, the cells were exposed to stress conditions including serum starvation, treatment with the DNA damaging agent doxorubicin (500 nM), or treatment with Herceptin (20 µg/mL), a therapeutic antibody against human epidermal growth factor receptor-2 (HER2) for 48 h. Herceptin was chosen for this study because both BT474 and SKBR3 cell lines express robust levels of HER2. The cell death induced by these treatments was attenuated in KRT19
shRNA cells compared with that of Cont shRNA cells (Fig. 2C, upper panels) . We also demonstrated efficient down-regulation of the apoptotic markers of proteolytic cleavage of caspase3 and poly ADP ribose polymerase (PARP) after treatment with doxorubicin or Herceptin in KRT19 shRNA cells compared with Cont shRNA cells ( Fig. 2C, lower Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 5, 2013; DOI: 10.1158/1078-0432.CCR-12-3295 KRT19 regulates cell proliferation and migration effect of KRT19 overexpression on cytotoxicity of doxorubicin ( Supplementary Fig. S1G ). These results indicate that KRT19 silencing might confer resistance to apoptosis. Together, the results of Figure 1 and 2 suggest that KRT19 might act as a tumor suppressor in human breast cancer through the regulation of cancer cell proliferation and survival.
KRT19 silencing induces Akt activity through down-regulation of PTEN mRNA expression
To investigate the mechanisms responsible for KRT19 silencing-mediated up-regulation of cell proliferation, migration, invasion, and survival, we examined the status of intracellular signaling molecules. HER2 activates a number of intracellular signal cascades including the PI3K/Akt pathway (16) . We found that silencing of KRT19 induced down-regulation of HER2 ( Supplementary Fig. S3E ). We confirmed that KRT19 shRNA exclusively regulates its level and Akt signaling. We also examined the nuclear localization and transcriptional activity of FOXO, an transcription factor downstream of Akt1 that is negatively regulated by Akt activity (17) . Basal levels of FOXO-dependent transcriptional activities were effectively decreased by KRT19 silencing (Fig. 3B , right panel). Localization of ectopic FOXO3a in nucleus was also reduced in KRT19 shRNA cells, as revealed by cell fractionation assays ( Supplementary Fig. S3B ). The results in Figure 3A and 3B collectively suggest that silencing of KRT19 efficiently increased PI3K/Akt-downstream signaling.
To investigate the mechanism by which KRT19 silencing up-regulated the Akt pathway despite down-regulation of HER2 levels, we considered the possibility that KRT19 silencing regulates PTEN, a negative modulator of the PI3K/Akt pathway. We found that mRNA and protein levels of PTEN were significantly down-regulated in KRT19 shRNA cells compared with those of Cont shRNA cells Transcriptional activity of a reporter construct containing the promoter region of PTEN (-500/+273 bp) was also decreased by KRT19 silencing (Fig. 3D ). Accordingly, co-transfection of KRT19 increased PTEN promoter activity in 293T cells ( Supplementary Fig. S3D ). To determine whether KRT19 directly affects the stability of PTEN protein, we measured PTEN protein level after treatment with MG132, a 26S proteasome inhibitor. MG132 treatment resulted in a slight increase in of PTEN protein level ( Supplementary Fig. S4A ). PTEN protein level is known to be regulated by NEDD4-1
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Author Manuscript Published OnlineFirst on July 5, 2013; DOI: 10.1158/1078-0432.CCR-12-3295 KRT19 regulates cell proliferation and migration E3 ligase via ubiquitination-mediated proteosomal degradation (18) . Although the decreased basal expression level of PTEN in KRT19 shRNA cells was restored by treatment with MG132, the levels were still lower than the PTEN level in Cont shRNA cells after MG132 treatment ( Supplementary Fig.   S4A , lane 2 vs. 4 and lane 6 vs. 8). These results suggest that silencing of KRT19 did not downregulate PTEN protein level through a decrease in protein stability of PTEN. In cycloheximide decay assays, the decay slopes of PTEN were similar between KRT19 and Cont shRNA cells ( Supplementary Fig. S4B ). These findings confirmed that transcriptional control of PTEN mRNA is the major molecular mechanism responsible for KRT19 silencing-induced down-regulation of PTEN.
KRT19 regulates nuclear localization of Egr1 transcriptional factor
We next focused on transcription factors that might be responsible for the regulation of PTEN transcription. Egr1 is a well-known transcription factor that up-regulates PTEN transcription (6) . We investigated the effect of Egr1 knock-out on PTEN expression in vivo using an Egr1-deficient mouse model. As depicted in Figure 4A , western blot analyses revealed that PTEN protein level was downregulated in the mammary glands of Egr1-deficient mice compared with their wild type littermates.
Phosphorylated Akt was up-regulated in Egr1-deficient mice as a result of reduced PTEN expression.
Based on these in vivo observations, we investigated whether the KRT19 silencing-induced downregulation of PTEN is mediated by Egr1. Interestingly, we observed that both mRNA and protein expression levels of Egr1 were decreased by KRT19 silencing in HER2-positive MCF7 HER2, BT474, and SKBR3 cells, but not in HER2-negative/low T47D and MCF-7 vec cells ( Fig. 4B , 4C, Supplementary Fig. S5A and S5B). To explain the differential effect of KRT19 silencing on Egr1 expression between HER2-positive and -negative/low cells, we examined the possible modulation of extracellular signal-regulated kinase (ERK) signaling by KRT19 silencing because Egr1 transcription is regulated by the ERK/E twenty-six (ETS)-like transcription factor (Elk) pathway (19, 20) . Our results indicated that activities of ERK signaling after KRT19 silencing were vastly different between HER2-positive and -negative/low cells ( Supplementary Fig. S5C ). In HER2-positive MCF7 HER2, BT474, and SKBR3 cells, the activities of c-Raf/mitogen-activated protein kinase kinase (MEK), ERK, and Elk were down-regulated by KRT19 silencing, as determined by their phosphorylation status, while activities of c-Raf/MEK/ERK/Elk in HER2-negative/low T47D, and MCF7 vec cells were not significantly changed after KRT19 silencing. Needless to say, activation of the ERK pathway in HER2 negative/low cells was achieved by a HER2-independent mechanism, while that of HER2positive cells was HER2-dependent (21, 22) . Down-regulation of HER2 by KRT19 silencing ( 
KRT19 mediates association between Egr1 and Imp7
The phosphorylated S/T-P-S/T NTS domain regulates nuclear localization of molecules through interaction with Imp7 (10). Egr1 contains a NTS domain that binds Imp7 for nuclear localization (12) .
Based on these findings, we were interested in whether KRT19 silencing affected the association between Egr1 and Imp7. Co-immunoprecipitation studies ( Fig. 5A ) revealed that KRT19, Egr1, and Imp7 formed a ternary complex in all five cell lines. Control immunoprecipitates with normal IgG did not contain KRT19, Egr1, or Imp7. In KRT19 shRNA cells, the Egr1-Imp7 association was significantly impaired compared with control cells (Fig. 5B ). Therefore KRT19 might facilitate association between Egr1 and Imp7 thereby inducing nuclear targeting of Egr1.
In addition to the NTS domain, classical NLS domain in the zinc finger domain regulates nuclear localization of Egr1 (11) . If KRT19-mediated increased association between Egr1 and Imp7 only occur through potentiation of Imp7 binding to NTS domain of Egr1, the classical NLS-mediated nuclear localization of Egr1 may still happen in KRT19-silenced cells. So we further hypothesized that Egr1 nuclear localization by classical NLS domain was also achieved by a KRT19-dependent mechanism. Because NLS domain of Egr1 plays a dominant role in Egr1 nuclear localization as compared to NTS domain (12) , it was indeed less likely to conclude that KRT19 silencing-induced perturbation in nuclear targeting of Egr1 is mainly dependent on decreased binding of Imp7 to NTS domain of Egr1. To precisely determine the interaction motifs in Egr1-KRT19-Imp7 ternary structure, we sub-cloned full length Egr1 (WT), NLS domain deletion mutant (ΔNLS), NTS alanine substitution mutant (APA) and NLS/NTS double mutant (ΔNLS/APA). Egr1 constructs were transiently cotransfected with KRT19 wild type construct into 293T cells and the cell lysates were divided into nuclear and cytosolic fractions. Our results showed that KRT19 could effectively translocate Egr1-WT, ΔNLS and APA from cytosol to nucleus, but not double mutant (Fig. 5C ). In addition, Egr1-WT and Egr1-APA could effectively bind KRT19 while Egr1-ΔNLS and double mutant exhibited reduced affinity toward KRT19 ( Fig. 5D , 1 st and 2 nd panel, lane 3, 7 vs 5, 9). These data indicated that the binding of Egr1 to KRT19 is mainly mediated by the interaction between NLS domain of Egr1 and KRT19. When the interaction between Imp7 and Egr1 was examined, both Egr1-WT and Egr1-ΔNLS Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 5, 2013; DOI: 10.1158/1078-0432.CCR-12-3295 KRT19 regulates cell proliferation and migration could effectively bind Imp7 and this association between Imp7 and Egr1 was enhanced by KRT19 coexpression ( Fig. 5D , 3 rd panel, lane 2 vs 3 and 4 vs 5). However, both Egr1-APA and double mutant could not bind Imp7 (lane 6-9). Interestingly, we found that the association between KRT19 and Imp7 was Egr1-independent phenomena, since KRT19 could bind Imp7 even in the presence of Egr1 double mutant in which the interaction site between Egr1 (NLS) and KRT19 and the site between Egr1 (NTS) and Imp7 were deleted (Fig. 5D, 4 th panel, lane 9) . Taken together, the data in Fig. 5 collectively suggest that KRT19 is a necessary requirement for the association between Imp7 and NTS domain of Egr1.
KRT19 regulates in vivo tumorigenesis via modulation of Egr1 subcellular localization in mouse xenograft model
We next examined the effect of KRT19 silencing on in vivo tumor formation using a xenograft mouse model (Fig. 6A ). When 1×10 6 SKBR3 KRT19 shRNA and Cont shRNA cells were inoculated subcutaneously into both sides of the lower flank of BALB/C nude mice, none of the mice examined developed tumors ( Fig. 6A and B) . When 5×10 6 SKBR3 KRT19 shRNA cells were inoculated, all mice developed xenograft tumors. In contrast, tumors developed at only two out of 10 injection sites inoculated with 5×10 6 SKBR3 Cont shRNA cells. In addition, the weights of SKBR3 KRT19 tumors were approximately 6-fold higher than those of control tumors (Fig. 6C) . Immunohistochemistry experiments revealed that SKBR3 KRT19 tumors exhibited up-regulation of phosphoryated Akt and down-regulation of PTEN compared with control cell tumors (Fig. 6D ). The KRT19 level was still efficiently down-regulated in SKBR3 KRT19 shRNA tumors. These results are in accordance with those obtained using in vitro cultured cells in Figure 3 . We also confirmed that Egr1 nuclear localization was significantly impaired in SKBR3 KRT19 shRNA tumors ( Fig. 6E ) compared with control tumors whereas the subcellular distribution of Imp7 appeared to be similar in the two types of tumor.
Discussion
This study uncovers a new mechanism by which KRT19-mediated association between Egr1 and Imp7 down-regulates breast cancer cell proliferation, migration, invasion, and survival through upregulated transcription of PTEN and subsequent inhibition of Akt by promoting nuclear localization of Egr1 both in vitro and in vivo. Egr1 is a crucial transcription factor that is induced by stress, injury, mitogens, and differentiation signals (7, 23, 24) . Egr-1 up-regulates the expression of multiple genes, KRTs are dynamically regulated intermediate filaments that are fully integrated within the cellular framework and interact with a range of cellular proteins (1) . Many of these proteins, including various kinases, receptors, adaptors, and other types of effector, function in signaling networks that regulate the cell cycle, apoptosis, and the cellular response to stress (1) . It has been shown that KRT8 and KRT18 bind tumor necrosis factor receptor-2 (TNFR2), reflecting their ability to specifically interact with other signaling proteins (29). This interaction affects the TNF-dependent activation of downstream effectors such as c-Jun N-terminal kinase (JNK) and NFκB. KRT17 up-regulates protein synthesis and cell growth via the Akt/mTOR pathway by binding to the adaptor protein 14-3-3σ (30).
One of the most interesting keratins is KRT19, the smallest known intermediate filament protein (31).
KRT19 has a highly conserved α-helical central domain that is essential for filament formation, but lacks the C-terminal non-helical tail domain present in other acidic KRTs (32) . A previous study demonstrated that absence of KRT19 induced skeletal myopathy in a KRT19 knock-out mouse model (33) . However, compared with other KRT isoforms, KRT19-mediated intracellular signaling has not been widely studied.
It was previously reported that KRT19 expression is coupled with HER2 expression in breast cancer (34) . Our in silico analysis also revealed that KRT19 expression is positively correlated with HER2 ( Supplementary Fig. S7 ). In our experiments, when KRT19 was knocked-down, HER2 expression was dramatically down-regulated. Tumorigenicity of HER2-amplified breast cancer cells such as SKBR3 and BT474 is presumably dependent on HER2 (35, 36) . Since a HER2-targeted therapy would be used for a HER2 overexpressing tumor, this may suggest that any intracellular genetic event(s) which completely silences KRT19 levels could lead to resistance to HER2-targeted therapies. However, it is also possible that a modest decrease in HER2 level by attenuation of KRT19 would lead to a decrease in tumorigenic potential of HER2 by inhibition of HER2-downstream signaling.
It was reported that Egr1 nuclear localization and transcriptional activity are regulated by α-tubulin cytoskeleton protein in benign prostate cells but not in malignant prostate cells (37) . The authors showed that Egr1 associates with α-tubulin in benign prostate cells but not in prostate cancer cells using immunofluorescence confocal analyses and co-immunoprecipitation experiments. Furthermore, α-tubulin-mediated Egr1 localization in benign prostate cells is unique among the Egr family since other related proteins including Egr2, Egr3, Sp1, or WT1 do not exhibit such behavior. Interestingly, they also showed that KRT co-localized with Egr1 in the perinuclear region of DU-145 prostate cancer cells using pan-KRT antibody and immunofluorescence confocal analyses. We speculate that They also showed that Imp7-dependent nuclear localization of Egr1 is not solely dependent on the previously identified classical NLS.
Based on these previous studies, we investigated the possibility that KRT19 might mediate nuclear localization of Egr1 by facilitating Egr1-Imp7 complex formation in breast cancer cells. KRT19 was indeed required for proper Egr1 nuclear localization via formation of a KRT19-Egr1-Imp7 ternary complex. Upon nuclear localization of Egr1, PTEN was expressed through transcriptional activity of Egr1, resulting in down-regulation of PI3K/Akt activity in breast cancer cells. The PI3K/Akt pathway is centrally involved in cell proliferation, migration, invasion, and survival (9, 38) .
As summarized in Figure 6F , KRT19 silencing up-regulated the activity of Akt, and subsequently increased cell proliferation, migration, invasion, and survival. It was recently reported that activation of Akt could be subject to negative feedback regulation by PTEN (7) . Akt-mediated phosphorylation of Egr1 induces SUMOylation of Egr1 by p14ARF, which is required for Egr1-mediated transcription of its target genes including PTEN (7) . We also identified KRT19 as a necessary component of the negative feedback loop that down-regulates PI3K/Akt pathway. Although KRT19-silenced cells exhibit high Akt activity, the absence of KRT19 fails to establish negative feedback on PI3K/Akt pathway due to impaired nuclear import of Egr1. The lack of negative feedback regulation of Akt activity may account for the dramatic rise in Akt activity as well as the tumorigenic potential of KRT19 silenced cells in vivo.
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